S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
NASDAQ:COCP

Cocrystal Pharma (COCP) Stock Price, News & Analysis

$1.53
+0.03 (+2.33%)
(As of 04/19/2024 08:50 PM ET)
Today's Range
$1.48
$1.60
50-Day Range
$1.40
$1.60
52-Week Range
$1.33
$3.29
Volume
7,600 shs
Average Volume
13,674 shs
Market Capitalization
$15.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Cocrystal Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
553.6% Upside
$10.00 Price Target
Short Interest
Healthy
0.07% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.18) to ($1.46) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.57 out of 5 stars

Medical Sector

434th out of 907 stocks

Pharmaceutical Preparations Industry

196th out of 422 stocks

COCP stock logo

About Cocrystal Pharma Stock (NASDAQ:COCP)

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

COCP Stock Price History

COCP Stock News Headlines

Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Recap: Cocrystal Pharma Q4 Earnings
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Cocrystal Pharma Inc (COCP)
Cocrystal Pharma Inc COCP
Recap: Cocrystal Pharma Q3 Earnings
See More Headlines
Receive COCP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cocrystal Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/28/2024
Today
4/21/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:COCP
Fax
N/A
Employees
12
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+553.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-17,980,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.59 per share

Miscellaneous

Free Float
7,624,000
Market Cap
$15.56 million
Optionable
Not Optionable
Beta
1.34
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Roger D. Kornberg Ph.D. (Age 77)
    Co-Founder, Chairman of the Board, Chief Scientist & Chairman of Scientific Advisory Board
    Comp: $125k
  • Dr. Sam Lee Ph.D. (Age 64)
    Co-Founder, Co-CEO & President
    Comp: $521.38k

COCP Stock Analysis - Frequently Asked Questions

Should I buy or sell Cocrystal Pharma stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cocrystal Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" COCP shares.
View COCP analyst ratings
or view top-rated stocks.

What is Cocrystal Pharma's stock price target for 2024?

1 equities research analysts have issued twelve-month target prices for Cocrystal Pharma's shares. Their COCP share price targets range from $10.00 to $10.00. On average, they predict the company's share price to reach $10.00 in the next year. This suggests a possible upside of 553.6% from the stock's current price.
View analysts price targets for COCP
or view top-rated stocks among Wall Street analysts.

How have COCP shares performed in 2024?

Cocrystal Pharma's stock was trading at $1.7222 at the beginning of the year. Since then, COCP shares have decreased by 11.2% and is now trading at $1.5299.
View the best growth stocks for 2024 here
.

Are investors shorting Cocrystal Pharma?

Cocrystal Pharma saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 5,000 shares, an increase of 35.1% from the March 15th total of 3,700 shares. Based on an average daily volume of 13,900 shares, the short-interest ratio is presently 0.4 days. Approximately 0.1% of the shares of the company are sold short.
View Cocrystal Pharma's Short Interest
.

When is Cocrystal Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our COCP earnings forecast
.

How were Cocrystal Pharma's earnings last quarter?

Cocrystal Pharma, Inc. (NASDAQ:COCP) posted its quarterly earnings results on Thursday, March, 28th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.13.

When did Cocrystal Pharma's stock split?

Cocrystal Pharma's stock reverse split on Tuesday, October 11th 2022. The 1-12 reverse split was announced on Tuesday, October 11th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What other stocks do shareholders of Cocrystal Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cocrystal Pharma investors own include Moderna (MRNA), Hello Group (MOMO), Intra-Cellular Therapies (ITCI), Impala Platinum (IMPUY), GenMark Diagnostics (GNMK), Gevo (GEVO), Auxly Cannabis Group (CBWTF), Bionano Genomics (BNGO), Blink Charging (BLNK) and Bilibili (BILI).

How do I buy shares of Cocrystal Pharma?

Shares of COCP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:COCP) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners